Precision Neuroscience Secures $102 Million to Accelerate Development of AI-Driven Brain Implant for Paralysis Treatment

Precision Neuroscience, a leader in brain-computer interface (BCI) technology, has successfully raised $102 million in Series C funding, bringing its total capital to $155 million. Led by General Equity Holdings and joined by investors such as B Capital and Duquesne Family Office, the new funding will enable the company to scale its operations, expand clinical research, and refine its AI-powered brain implant. This device is designed to help individuals with severe paralysis control digital devices, such as smartphones and computers, using only their thoughts. Precision aims to revolutionize how people with paralysis interact with the world, offering new possibilities for communication, independence, and employment.

The company’s innovative roadmap extends beyond paralysis treatment, with plans to address neurological conditions like obsessive-compulsive disorder and depression. “Our goal is to develop a product that is safe, scalable, and able to treat a broad range of neurological disorders,” said Michael Mager, CEO and co-founder of Precision Neuroscience. The company’s focus on severe spinal cord injuries, stroke, and ALS represents an initial step toward creating a universal treatment that could dramatically impact millions of lives.

The BCI industry is experiencing rapid growth, with the commercial BCI market expected to reach $400 billion in the U.S. alone. “BCI technology is at an inflection point,” said Andrew Bellas, Managing Partner at General Equity Holdings. “Precision’s cutting-edge technology is set to unlock unprecedented potential, both in medicine and beyond.” With a focus on advancing both hardware and software to connect with the brain, Precision’s breakthrough innovation has the potential to drastically improve the lives of millions, offering hope for individuals with neurological conditions previously thought unmanageable.